7:59 AM
 | 
Oct 20, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Exelixis, Ipsen report additional Phase II data for cabozantinib in untreated RCC

In September, Exelixis Inc. (NASDAQ:EXEL) and partner Ipsen Group (Euronext:IPN; Pink:IPSEY) reported additional data from the open-label Phase II CABOSUN trial in 157 patients with previously untreated advanced renal cell carcinoma (RCC) showing that first-line treatment with once-daily 60 mg oral cabozantinib (XL184) led to a median progression-free survival (PFS), the primary endpoint, of 8.6 months as assessed by a blinded independent radiology review committee (IRC) vs. 5.3 months for Sutent sunitinib (HR=0.48, 95% CI: 0.31, 0.74, p=0.0008). On a secondary endpoint, cabozantinib led to an objective...

Read the full 416 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >